Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

TyraTech Secures New Patent

16 Oct 2012 11:40

RNS Number : 8033O
TyraTech, Inc.
16 October 2012
 

TyraTech, Inc.

(the "Company" or "TyraTech")

 

TyraTech Secures New Composition Patent for Human and Animal Health

 

Patent Protects New Human and Animal Health Products and Pipeline.

TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has received notice from the United States Patent and Trademark Office granting a new patent for the Company's novel anti-parasitic and pest control composition.

The Directors of the Company believe that this patent is an important addition to TyraTech's intellectual property portfolio as it protects a number of new product offerings, including its new head lice flea and tick formulations. It will provide immediate support for TyraTech's head lice treatment range, as the Company plans to launch its first product in this area in 2013. This patent will also provide support and protection of the Company's pipeline of flea and tick control solutions for companion and production animals.

Alan Reade, Executive Chairman of the Company said, "This new addition to our intellectual property portfolio further confirms TyraTech as an innovative human and animal health company. This patent, in particular, provides protection and creates an array of exciting human and animal health market opportunities. Additionally, it validates our position at the forefront of developing best in class solutions that deliver the highest levels of efficacy and safety for people, pets, and production animals."

The issuance of this patent raises TyraTech's patent portfolio to twelve United States and international patents protecting its proprietary screening platform and compositions.

 

###

For further information please contact:

TyraTech Inc.Alan Reade, Executive ChairmanTel: +1 919 415 4310

Peter Jerome, Chief Financial OfficerTel: +1 919 415 4280

N+1 Brewin, Nominated Adviser and Joint BrokerAubrey Powell / Robert Beenstock / Alex WrightTel: +44 20 3201 3710

First Columbus LLP, Joint BrokerChris CrawfordTel: +44 20 3002 2070

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUNORRUBARAAA
Date   Source Headline
26th Sep 20087:00 amRNSInterim Results
22nd Sep 20087:00 amRNSTrading Update
15th Sep 200812:28 pmRNSNotice of Results
29th Aug 20083:48 pmRNSRestructuring Closed
28th Aug 20087:00 amRNSChange of Shareholding
18th Aug 20086:11 pmRNSSpecial Meeting Result
8th Aug 20087:00 amRNSCircular
4th Aug 20087:00 amRNSCirc re. XL TechGroup
30th Jun 20082:45 pmRNSAnnual Report and Accounts 20
27th Jun 20088:17 amRNSTemporary Suspension of Tradi
9th Jun 20085:07 pmRNSLoan Settlement
15th May 200812:30 pmRNSAGM Result
17th Apr 20087:01 amRNSEmployee Loan
7th Apr 20087:01 amRNSBoard Changes
2nd Apr 20087:01 amRNSTyraTech Final Results
2nd Apr 20087:01 amRNSPreliminary Results
17th Mar 20087:02 amRNSAppointment
27th Feb 20087:01 amRNSOperating update
10th Jan 20087:00 amRNSArysta Milestone Payments
10th Jan 20087:00 amRNSArysta milestone payment
17th Dec 20077:01 amRNSTyraTech Kraft payment
17th Dec 20077:01 amRNSKraft milestone payment
19th Nov 20077:05 amRNSTyraTech Sustainable Business
19th Nov 20077:01 amRNSSustainable Business Launch
16th Oct 20077:05 amRNSTyraTech product launch
16th Oct 20077:01 amRNSProduct launch & first order
4th Oct 20077:01 amRNSnew borrowing facility
2nd Oct 20077:01 amRNSDirector/PDMR Shareholding
26th Sep 20077:01 amRNSTyraTech Interim Results
26th Sep 20077:01 amRNSInterim Results
15th Aug 200710:15 amRNSCompliance of AiM Rule 26
9th Jul 20074:00 pmRNSVP appointment
1st Jun 20078:51 amRNSTyraTech 1st day of Dealings
1st Jun 20078:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.